- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00002261
A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers
To determine the physiological and immunological responses in healthy HIV seronegative adult volunteers vaccinated with a) the HIVAC-1e (vaccinia-HIV) vaccine expressing the envelope glycoproteins of HIV and b) the Wyeth smallpox vaccine. The parameters to be studied will include:
- The course of physiological responses to vaccination, including (a) lesion development, progression, and resolution; (b) physiological changes such as temperature, malaise, itching at the site, etc. and (c) any observable AE.
- The appearance, identity, quantity, and duration of humoral antibodies against HIV and vaccinia virus.
- The appearance, identity, quantity, and duration of cell-mediated immunity against HIV and vaccinia virus.
- The adequacy of a procedure using a special dressing to contain viral shedding from the vaccination site.
- The safety, humoral and cellular immune responses of a booster injection of the recombinant subunit gp160 vaccine (MicroGeneSys) in HIVAC-1e recipients.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Connecticut
-
Wallingford, Connecticut, United States, 064927600
- Bristol - Myers Squibb Co
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Concurrent Medication:
Allowed:
- All drugs, medications, and therapy which, by virtue of direct pharmacologic action or possible drug interaction, could influence the intended effects of the study vaccine or mask its side effects may be concomitantly administered only by prescription by the Principal Investigator and must be documented on the case report form (CRF).
- Any drug, even aspirin, which is administered after vaccination and during the follow up periods must be documented on the patient's CRF.
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
- Failure to meet any criteria listed under Inclusion Criteria.
- Development of active eczema or other skin condition which would increase the risk of secondary vaccinia lesions.
- Appearance of serologic or clinical evidence of HIV infection prior to vaccination.
- Current evidence of clinically active viral infections such as Mononucleosis, Epstein-Barr Virus, or cytomegalovirus which may affect immunocompetence.
- Active and overt parasitic, mycobacterial, or pyogenic infections that affect tests designated in Inclusion Criteria.
Concurrent Medication:
Excluded:
- All drugs, medications and therapy not prescribed by the Principal Investigator, and not documented on the case report form (CRF).
- Any drug, even aspirin, which is administered after vaccination and during the follow up periods which is not documented on the patient's CRF.
Patients with the following are excluded:
- Failure to meet any criteria listed under Inclusion Criteria.
- Appearance of serologic or clinical evidence of HIV infection prior to vaccination.
- Current evidence of clinically active viral infections.
- Active and overt parasitic, mycobacterial, or pyogenic infections that affect tests designated in Inclusion Criteria.
Risk Behavior:
Patients who do not agree to behave sexually in a manner that will minimize the risk of HIV infection for the duration of the study are excluded.
Patients must:
- Be HIV seronegative.
- Have excellent general health.
- Be unable to bear children.
- Have no immediate household contacts, sex partners, intimate contacts.
- Be free of clinical skin diseases.
- Have signed an informed consent.
- Control subjects receiving Smallpox vaccine will also be selected under the same inclusion criteria. They may be recruited from low risk behavior populations; from laboratory and hospital employees providing service to the study who would normally require Smallpox vaccination; and may be heterosexual, homosexual, or bisexual.
Patients must agree to behave sexually in a manner that will minimize the risk of HIV infection for the duration of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
Collaborators and Investigators
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 063A
- AI452-003001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on HIVAC-1e
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Cancer Institute (NCI)NRG OncologyCompletedRecurrent Uterine Corpus Sarcoma | Uterine CarcinosarcomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingInvasive Breast Carcinoma | HER2/Neu Negative | Bilateral Breast CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdult Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IIIC Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v6 and v7United States, Puerto Rico
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingEndometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Recurrent Uterine Corpus Cancer | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IVA Uterine Corpus Cancer... and other conditionsUnited States